4-(tert-Butyl)picolinamide | 920112-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(tert-Butyl)picolinamide
• 英文别名: 4-tert-butylpyridine-2-carboxamide
• CAS: 920112-75-0
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.23
• InChiKey: NXHJSKHLRMSGDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Priestley Eldon Scott

  公开号：US20100227894A1

  公开（公告）日：2010-09-09

  The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)的新型苯甲酰胺衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量A、W、Y、Z、R8和R9如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。
• MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Priestley Eldon Scott

  公开号：US20090281139A1

  公开（公告）日：2009-11-12

  The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

  本发明涉及一般的新型大环化合物，其化学式为（I）或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中变量A、B、L、M、W、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如本文中所定义。这些化合物是选择性抑制剂凝血因子VIIa的丝氨酸蛋白酶，可用作药物。
• Inhibitors of BCR-ABL mutants and use thereof
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10196378B2

  公开（公告）日：2019-02-05

  Inhibitor compounds of Bcr-Abl and Bcr-Abl mutants including Bcr-Abl T315I mutant protein are disclosed. Compositions comprising the inhibitor compounds and methods of using the compounds in the treatment of leukemia such as chronic myelogenous leukemia are also disclosed.

  本研究公开了 Bcr-Abl 和 Bcr-Abl 突变体（包括 Bcr-Abl T315I 突变蛋白）的抑制剂化合物。还公开了包含抑制剂化合物的组合物以及使用这些化合物治疗白血病（如慢性骨髓性白血病）的方法。
• Somatostatin modulators and uses thereof
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US11028068B2

  公开（公告）日：2021-06-08

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文描述了作为体生长抑素调节剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药剂，以及使用此类化合物治疗可受益于体生长抑素活性调节的病症、疾病或紊乱的方法。
• Inhibitors of BCR-ABL Mutants and Use Thereof
  申请人：The Regents of the University of Michigan

  公开号：US20180057479A1

  公开（公告）日：2018-03-01

  Inhibitor compounds of Bcr-Abl and Bcr-Abl mutants including Bcr-Abl T315I mutant protein are disclosed. Compositions comprising the inhibitor compounds and methods of using the compounds in the treatment of leukemia such as chronic myelogenous leukemia are also disclosed.